Baker & McKenzie assisted Cell Medica on the acquisition of privately-held Swiss biopharma company Delenex Therapeutics. By acquiring Delenex, Cell Medica has expanded its T-cell immunotherapy program, allowing it to accelerate the development of gene-modified immune cell products with enhanced potency for the treatment of cancer.

Cell Medica  is a cellular immunotherapy company, employing leading-edge technologies to develop cell-based therapies with the potential to transform the lives of cancer patients in the years ahead.  The company is also currently working in collaboration with the Baylor College of Medicine to develop next-generation cellular immunotherapies, for the treatment of cancers that do not respond to conventional therapies.

Delenex is a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex’s proprietary PENTRA® technology, which enables the rapid development of antibody therapeutics suitable for various routes of administration, will be integrated within Cell Medica’s development program to create next-generation cellular immunotherapies with improved functionality and specificity.

Cell Medica was advised by a Baker & McKenzie team led by Alexander Wyss, with assistance from Timo Leis, Julia Schieber, Marion Schnyder and Michelle Kalt. Alexander Wyss said, "It has been an honor to work on such a significant acquisition, which will allow Cell Medica to further develop their therapies and technology in the fight against cancer."

Gregg Sando, CEO of Cell Medica, said, “We are committed to transforming the treatment of cancer through the significant therapeutic potential of cellular immunotherapy. The acquisition of Delenex provides a key enabling technology for the development of an exciting pipeline of next generation CAR-modified cell therapies. We are delighted to welcome the talented team from Delenex."